达纳康治疗血管性认知功能损害的临床研究  

A clinical study of Tanakan in the vascular cognitive impairment

作　　者：刘汉兴[1] 章军建[1] 黄朝云[1] 杨四清[1] 

机构地区：[1]武汉大学中南医院神经科,430071

出　　处：《卒中与神经疾病》2004年第2期101-103,共3页Stroke and Nervous Diseases

基　　金：国家自然科学基金资助项目(编号:30270483)

摘　　要：目的 评价达纳康(Egb761)治疗血管性认知功能障碍的临床疗效和安全性。方法 110例血管性认知功能损害的病人随机分配到治疗组和对照组;治疗组服用达纳康,每次80 mg,每日3次,而对照组服用丹参片,每次2片,每日3次,疗程均为3个月,并应用MMSE和ADL量表评价其疗效。结果 治疗组MMSE评分增加较对照组多2.38,差异有统计学意义(P<0.01);治疗组ADL评分减少较对照组多0.41,但差异无统计学意义(P>0.05)结论 达纳康治疗血管性认知功能损害安全有效。Objective To assess the efficacy and safety of Tanakan in vascular cognitive impairment(VCI). Methods One hundred and ten patients with VCI were assigned randomly to treatment with Tanakan or Dan-shen. The test group was treated with Tanakan (80 mg Tid) and the control group was treated with Dan-shen (2 tables Tid). The duration of therapy was three months, MMSE and ADL were used to measure outcome. Results The Tanakan group had a MMSE score 2.38 points better than the Dan-shen group (P < 0.01) and an ADL score 0.41 points lower than the Dan-shen group (P >0.05). There was significant differenc between Tanakan group and Dan-shen group in VCI. Conclusions Tanakan is safe and appears capable of improving the cognitive performance of VCI patients.

关 键 词：达纳康 药物治疗 血管性认知功能损害 临床疗效 老年性痴呆 血管性痴呆 

分 类 号：R749.13[医药卫生—神经病学与精神病学] R972[医药卫生—临床医学]